Report
Martial Descoutures

Moderna : Un brevet challengé et un nouveau financement de la BARDA

>De nouvelles questions sur la protection brevetaire de sa LNP - En fin de semaine dernière, nous apprenions que l’USPTO validait un brevet détenu par la Biotech Arbutus concernant la synthèse de la LNP : nanoparticules lipidiques permettant le transfert de l’ARNm à l’intérieur de la cellule. La synthèse de cette LNP reste clé dans le process du vaccin à ARNm car valide l’intégration de l’ARNm sans détérioration. Nous risquons de partir dans une période d’incerti...
Underlying
Moderna Inc.

Moderna is creating a new generation of medicines based on messenger RNA to improve the lives of patients. The company uses its platform to identify and develop new mRNA medicines. When the company identifies a combination of platform technologies or programs across mRNA technologies, delivery technologies, and manufacturing processes that can enable shared product features across multiple potential mRNA medicines, it groups those programs as a modality. The company has created six modalities including prohylactic vaccines; cancer vaccines; intratumoral immuno-oncology; localized regenerative therapeuctics; systemic secreted therapeutics; and systemic intracellular therapeutics.

Provider
Oddo BHF
Oddo BHF

​Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

Analysts
Martial Descoutures

Other Reports on these Companies
Other Reports from Oddo BHF

ResearchPool Subscriptions

Get the most out of your insights

Get in touch